Literature DB >> 17936405

Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial.

Maurizio Infante1, Fabio Romano Lutman, Silvio Cavuto, Giorgio Brambilla, Giuseppe Chiesa, Eliseo Passera, Enzo Angeli, Maurizio Chiarenza, Giuseppe Aranzulla, Umberto Cariboni, Marco Alloisio, Matteo Incarbone, Alberto Testori, Anna Destro, Federico Cappuzzo, Massimo Roncalli, Armando Santoro, Gianluigi Ravasi.   

Abstract

BACKGROUND: Despite the high survival rates reported for screening-detected cases, the potential of screening of high-risk subjects for reducing lung cancer mortality is still unproven. We herewith present the baseline results of a randomized trial comparing screening for lung cancer with annual spiral computed tomography (CT) versus a yearly clinical review.
METHODS: Male subjects, 60-74 years old, and smokers of 20+ pack-years were enrolled. All participants received a baseline medical examination, chest X-rays (CXR) and sputum cytology upon accrual. Subjects randomized in the spiral CT group received a spiral CT scan at baseline, then yearly for the following 4 years. For controls, a yearly clinical examination was scheduled for the following 4 years.
RESULTS: 2472 subjects were randomized (1276 spiral CT arm, 1196 controls). Age, smoking exposure and co-morbid conditions were similar in the two groups. In the spiral CT group, 28 lung cancers were detected, 13 of which were visible in the baseline chest X-rays (overall prevalence 2.2%). Sixteen out of 28 tumours (57%) were stage I, and 19 (68%) were resectable. In the control group, eight cases were detected by the baseline chest X-rays (prevalence rate 0.67%), four (50%) were stage I, and six (75%) were resectable.
CONCLUSIONS: Baseline lung cancer detection rate in the spiral CT arm was higher than in most published studies. The stage I detection rate was increased four-fold by spiral CT versus chest X-rays. However, more tumours in an advanced stage were also detected by CT. The high resection rate of screening-detected patients suggests a possible increase in cure rate. However, longer follow-up is required for definitive conclusions. This trial has been registered at www.Clinicaltrials.gov, registration No. NCT00420862.

Entities:  

Mesh:

Year:  2007        PMID: 17936405     DOI: 10.1016/j.lungcan.2007.08.040

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  44 in total

Review 1.  Lung cancer screening: an update, discussion, and look ahead.

Authors:  Peter J Mazzone
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

2.  The National Lung Screening Trial: overview and study design.

Authors:  Denise R Aberle; Christine D Berg; William C Black; Timothy R Church; Richard M Fagerstrom; Barbara Galen; Ilana F Gareen; Constantine Gatsonis; Jonathan Goldin; John K Gohagan; Bruce Hillman; Carl Jaffe; Barnett S Kramer; David Lynch; Pamela M Marcus; Mitchell Schnall; Daniel C Sullivan; Dorothy Sullivan; Carl J Zylak
Journal:  Radiology       Date:  2010-11-02       Impact factor: 11.105

Review 3.  European and North American lung cancer screening experience and implications for pulmonary nodule management.

Authors:  Arjun Nair; David M Hansell
Journal:  Eur Radiol       Date:  2011-08-10       Impact factor: 5.315

Review 4.  Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals.

Authors:  Jiu-Wei Cui; Wei Li; Fu-Jun Han; Yu-Di Liu
Journal:  Transl Lung Cancer Res       Date:  2015-06

Review 5.  Small pulmonary nodules in baseline and incidence screening rounds of low-dose CT lung cancer screening.

Authors:  Joan E Walter; Marjolein A Heuvelmans; Matthijs Oudkerk
Journal:  Transl Lung Cancer Res       Date:  2017-02

6.  Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces false-positive referrals.

Authors:  Marjolein A Heuvelmans; Matthijs Oudkerk; Geertruida H de Bock; Harry J de Koning; Xueqian Xie; Peter M A van Ooijen; Marcel J W Greuter; Pim A de Jong; Harry J M Groen; Rozemarijn Vliegenthart
Journal:  Eur Radiol       Date:  2013-03-19       Impact factor: 5.315

Review 7.  Implementing lung cancer screening in the real world: opportunity, challenges and solutions.

Authors:  Robert J Optican; Caroline Chiles
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 8.  Lung cancer screening.

Authors:  U Pastorino
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

9.  Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.

Authors:  Rachel M Ostroff; William L Bigbee; Wilbur Franklin; Larry Gold; Mike Mehan; York E Miller; Harvey I Pass; William N Rom; Jill M Siegfried; Alex Stewart; Jeffrey J Walker; Joel L Weissfeld; Stephen Williams; Dom Zichi; Edward N Brody
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

10.  The potential for using risk models in future lung cancer screening trials.

Authors:  John K Field; Olaide Y Raji
Journal:  F1000 Med Rep       Date:  2010-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.